by NMS Group | Jun 30, 2021 | News
Nerviano, 30 June 2021 Accelera Srl and BiomimX® Srl have signed a non-exclusive commercial agreement following an intense scientific collaboration aimed at introducing and applying new technological solutions to the drug discovery process. The commercial agreement...
by NMS Group | May 17, 2021 | News
Nerviano, 17 May 2021 The relationship between Accelera and CROss Alliance® started a decade ago and since then we have renewed our collaboration during the years. Our specializations, preclinical and early phase clinical development respectively, our shared values...
by NMS Group | May 6, 2021 | News
Nerviano, 6 May 2021 NerPharMa, a veteran CDMO with a specialization in oncology small molecule drug manufacture and a member of NMS Group, has announced today a Partnership Agreement with ICROM srl, aiming for collaboration on commercial production of High Potent...
by NMS Group | Feb 9, 2021 | 2021, News
Nerviano, 9 February 2021 NMS Group has been named the winner of the “Value creators’ category at the prestigious ‘China Awards 2021′ during the online event held by the Italy China Foundation on Monday 8 February 2021. The “Value creators’...
by NMS Group | Dec 1, 2020 | 2020, News
Nerviano, 01.12.2020 Nerviano Medical Science Srl, the NMS Group subsidiary specialized in research and development of innovative oncological drugs, today announced the recent approval of a phase I clinical study for its PARP inhibitor (NMS-03305293) by China National...
by NMS Group | Nov 30, 2020 | 2020, News
Nerviano, 30.11.2020 dMed Company (Shanghai) Ltd. congratulated the recent approval of a PARP inhibitor (NMS-03305293 capsules) of its collaborator NMS Group, an Italian oncology drug discovery and development company, by the National Medical Products Administration...
Welcome and Check out our new motion picture!
Recent Comments